Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies
Go back to Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies| AbbVie (NYSE: ABBV) | Delayed: 264.33 -0.88 (0.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $265.21 | 52 Week High | $68.12 | |||
| Open | $266.00 | 52 Week Low | $50.71 | |||
| Day High | $269.39 | P/E | 57.34 | |||
| Day Low | $264.33 | EPS | $4.61 | |||
| Volume | 1,158,388 | |||||
